HCA monthly performance report
Check HCA's monthly returns, drawdown, and seasonality trends — updated every month.
HCA monthly report
—
Key takeaways
- HCA Healthcare (HCA) closed September 2026 at $427.71, up 3.20% for the month and +6.64% over the trailing 12 months.
- Year-to-date, HCA is −8.39%, underperforming the S&P 500 which has returned +11.70% YTD.
- The stock is trading −5.16% versus its 200-day moving average ($451.00), a cautious technical signal.
- Over the past three years, HCA has underperformed the S&P 500 by −4.43%, with a relative strength index reading of 97.4.
- Win rate over the trailing 39 months stands at 61.5% — 24 positive months versus 15 negative months.
HCA Healthcare ended September 2026 at $427.71, posting a monthly return of +3.20%. The S&P 500 returned −0.70% over the same window, leaving relative performance at +3.90%.
The current quarter stands at +9.70% (Q3 2026 (QTD)), while medium-term trend remains soft: price is −5.16% versus the 200-day moving average ($451.00).
Year-to-date, HCA is −8.39% against SPY +11.70%, a gap of −20.08%. The stock is currently −23.15% below its 52-week high, with maximum 3-year drawdown at −33.63%.
| Period | HCA | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −0.31% | −0.12% | −0.19% |
| 1 Week | +0.18% | −0.34% | +0.52% |
| 1 Month | +3.20% | −0.70% | +3.90% |
| 3 Months | +7.75% | +2.80% | +4.96% |
| 6 Months | −19.75% | +13.85% | −33.60% |
| YTD | −8.39% | +11.70% | −20.08% |
| 12 Months | +6.64% | +15.01% | −8.37% |
| 3 Years | +67.26% | +71.69% | −4.43% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2025 | +14.12% |
| #2 | Jul 2024 | +13.00% |
| #3 | Mar 2025 | +12.81% |
| #4 | Jan 2024 | +12.64% |
| #5 | Nov 2023 | +10.76% |
| Rank | Month | Return |
|---|---|---|
| #1 | May 2026 | −12.87% |
| #2 | Oct 2024 | −11.73% |
| #3 | Sep 2023 | −11.29% |
| #4 | Mar 2026 | −10.66% |
| #5 | Jul 2023 | −10.11% |
| Quarter | Return |
|---|---|
| Q2 2025 | +10.87% |
| Q3 2025 | +11.25% |
| Q4 2025 | +9.54% |
| Q1 2026 | +1.37% |
| Q2 2026 | −17.61% |
| Q3 2026 (QTD) | +9.70% |
| Year | Return |
|---|---|
| 2023 | +12.80% |
| 2024 | +10.89% |
| 2025 | +55.54% |
| 2026 | −8.39% |
| Metric | Value |
|---|---|
| 52-Week High | $556.52 (2026-03-12) |
| 52-Week Low | $354.00 (2026-07-14) |
| Current Price | $427.71 |
| 200-Day Moving Average | $451.00 |
| Price vs 200DMA | −5.16% |
| 3-Year Maximum Drawdown | −33.63% (2026-06-04) |
| Current Drawdown from 52W High | −23.15% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 97.4 |
| 3-Year Excess Return vs S&P 500 | −4.43% |
| RS Peak | 139.6 (Mar 2026) |
| RS Trough | 82.9 (Jun 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was HCA's return for this report period?
HCA returned +3.20% in the latest monthly window ending 2026-09-18.
Has HCA outperformed SPY year to date?
YTD HCA: −8.39% vs SPY: +11.70%.
What is HCA's 12-month return?
+6.64% over the trailing 12 months.
Is HCA above or below its 200-day moving average?
Price is −5.16% versus 200DMA ($451.00).
What is the maximum drawdown in the 3-year window?
−33.63% on 2026-06-04.